טראוסולפן רז 5 גרם
raz pharmaceutics ltd, israel - treosulfan - אבקה להכנת תמיסה לאינפוזיה - treosulfan 5 g/vial - treosulfan
ציטראפליט
tradis gat ltd - citric acid anhydrous; light magnesium oxide; sodium picosulfate - אבקה להכנת תמיסה - citric acid anhydrous 10.97 g; light magnesium oxide 3.5 g; sodium picosulfate 10 mg - sodium picosulfate, combinations
ניטיודוט
hope pharmaceuticals ltd, israel - sodium nitrite; sodium thiosulfate - תמיסה להזרקה - sodium thiosulfate 250 mg / 1 ml; sodium nitrite 30 mg / 1 ml - thiosulfate
סודיום תיוסולפט 250 מגמל
hope pharmaceuticals ltd, israel - sodium thiosulfate - תמיסה להזרקה - sodium thiosulfate 250 mg / 1 ml - thiosulfate
קלופידוגרל טבע
teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or
קלופידוגרל טבע
teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or
פיקו סלקס קרנברי
ferring pharmaceuticals ltd - citric acid anhydrous; magnesium oxide; sodium picosulfate - אבקה להכנת תמיסה - citric acid anhydrous 12 g; magnesium oxide 3.5 g; sodium picosulfate 10 mg - sodium picosulfate, combinations
קלופידוגרל טבע
teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel
פיקו - סלקס אורנג'
ferring pharmaceuticals ltd - citric acid anhydrous; magnesium oxide; sodium picosulfate - אבקה להכנת תמיסה - sodium picosulfate 10 mg; citric acid anhydrous 12 g; magnesium oxide 3.5 g - citric acid - citric acid - to clean the bowel prior to x-ray examination, endoscopy or surgery.
אינטפריטי וטרינרי
euromar ltd - avilamycin - פרמיקס - avilamycin 100 g/kg